Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Huang, Shushu; Lin, Hua; Zhu, Xiaodong; Chen, Xin; Fan, Lu; Chang-chang, Liu

doi:10.5603/ep.2014.0014

Cited by 15 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite increasing evidence showing worse QOL in OP patients, little is known regarding interventions improving QOL, particularly in elderly patients. Recently, a study in China has found over two years of zoledronic acid treatment in women with postmenopausal OP can improve bone mineral density, and can help improve QOL[10]. …”

Section: Introductionmentioning

confidence: 99%

Quality of Life Is Related to Social Support in Elderly Osteoporosis Patients in a Chinese Population

Wang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

ObjectiveTo explore the association between quality of life and social support in elderly osteoporosis patients in a Chinese population.MethodsA total of 214 elderly patients who underwent bone mineral density screening were divided into two groups: elderly patients with primary osteoporosis (case group, n = 112) and normal elderly patients (control group, n = 102). Quality of life and social support were compared between the two groups.ResultsQuality of life and social support were significantly different between the case and control groups. The physical function, role-physical, bodily pain, general health, vitality, social-functioning, role-emotional and mental health scores in case group were significantly lower than those in the control group (P < 0.01). The objective support, subjective support, utilization of support, and total scores in case group were significantly lower than those in the control group (P < 0.01). Quality of life and social support were positively correlated in the case group (r = 0.672, P < 0.01).ConclusionQuality of life and social support in elderly patients with osteoporosis in China were poorer than in elderly patients without osteoporosis and were positively correlated. Our findings indicate that increased efforts to improve the social support and quality of life in elderly osteoporosis patients are urgently needed in China. Further longitudinal studies should be conducted to provide more clinical evidence to determine causative factors for the observed association between risk factors and outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of Life Is Related to Social Support in Elderly Osteoporosis Patients in a Chinese Population

Wang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Another study of zoledronic acid using Qualeffo over 12 months in women with a T score -2.5 or lower also showed an improvement of 20% in pain scores [15]. The least improvement was 7% using Zoledronic acid in women with T scores at the femur or spine below T-2.5 after 24 months [16]. The present study covers a median treatment time of 9 yr in the course of which there was a 26% improvement in pain in female patients (Tables 1 and 2).…”

Section: Discussionmentioning

confidence: 95%

Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate

Wilson

Mwj

2018

Journal of Bone Biology and Osteoporosis

View full text Add to dashboard Cite

Purpose: Bisphosphonates are valuable in reducing the incidence of fracture. Side effects limit persistence with oral therapy and long term studies of pain relief are difficult to pursue. Intravenous bisphosphonates offer an alternative treatment to oral bisphosphonates and are tolerated over a longer period. The use of Pamidronate, an intravenously administered bisphosphonate, to benefit pain and reduce fracture incidence in the long term has not been extensively investigated. The study aimed to investigate the effect of Pamidronate on pain, vertebral fracture incidence and Bone Mineral Density over 6 or more years.Methods: Patients were offered intravenous Pamidronate if oral treatment with bisphosphonates or Hormone replacement therapy had failed due to side effects, fractures continued on oral treatment or oesophageal reflux led to cessation of oral treatment. Pain was assessed using the Nottingham health profile; radiographs were used to evaluate vertebral fracture and DXA measured bone mineral density.Results: The primary outcome was the pain domain. Median patient follow up was 9 years. Pain had improved significantly (p = 0.03) and in 68% pain had either improved or remained unchanged. Vertebral fractures occurred in 14% of patients in the first 3 years, 9.5% in years 4-6, but increased in years 7-9 to 27%. Bone mineral density increased in the lumbar spine (p < 0.001) but not at the femoral neck.Conclusions: Pamidronate had a beneficial effect on pain over the period of the study. Vertebral fracture incidence increased after 6 years of Pamidronate, although spine BMD increased significantly.

show abstract

“… 15 , 16 Zoledronic acid (ZOL) is a third-generation, nitrogen-containing bisphosphonate, and a once-yearly intravenous infusion of ZOL 5 mg can ensure bisphosphonate adherence and persistence over 12-month interval. 17 , 18 Moreover, ZOL is the most potent inhibitor of farnesyl diphosphate synthase, resulting in strongly inhibiting bone resorption, increasing secondary mineralization for refilling of remodeling space and reducing the incidence of vertebral/non-vertebral fractures. 19 The therapeutic effect of PKP combined with ZOL infusion in the treatment of elderly OVCF is currently controversial.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly

Shi¹,

Zhang²,

Cheng³

et al. 2018

CIA

View full text Add to dashboard Cite

ObjectiveWe studied the efficacy of zoledronic acid (ZOL) infusion on radiographic and clinical outcomes after percutaneous kyphoplasty (PKP) for elderly patients with osteoporotic thoracolumbar fractures (osteoporotic vertebral compression fractures [OVCFs]).Materials and methodsWe retrospectively analyzed 95 elderly patients (age >65 years) with OVCF. All patients were followed up for 2 years. Thirty-two patients were treated with only once-yearly 5 mg ZOL infusion (ZOL group), 34 patients with only PKP (PKP group) and 29 patients received ZOL infusion 3 days after PKP (PKP+ZOL group).ResultsThere were no significant differences in the patients’ age, gender, body mass index, lumbar spine bone mineral density T-scores, baseline of Visual Analog Scale scores and Oswestry Disability Index scores (P>0.05). The postoperative vertebral heights of patients with OVCF after PKP and PKP+ZOL were 23.70±3.03 and 24.30±3.13 mm, respectively, which were significantly higher than that of patients in ZOL group (P<0.05). The reduction in degrees of kyphotic deformity in the PKP and PKP+ZOL groups were corrected to 8.4° and 8.7°. The bone mineral density T-scores of patients with OVCF in the ZOL group and PKP+ZOL group were significantly higher than that in the PKP group (P<0.05). The Visual Analog Scale and the Oswestry Disability Index scores of the PKP+ZOL and PKP groups were significantly lower than those of the ZOL group (P<0.05). The incidence of recompression vertebral fracture (RVF) in the PKP group was 14.7%, but there was no patient with RVF in the PKP+ZOL group (P<0.05).ConclusionOnce-yearly 5 mg ZOL infusion combined with PKP could provide beneficial effects in elderly osteoporotic patients with OVCF.

show abstract

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Cited by 15 publications

References 49 publications

Quality of Life Is Related to Social Support in Elderly Osteoporosis Patients in a Chinese Population

Quality of Life Is Related to Social Support in Elderly Osteoporosis Patients in a Chinese Population

Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate

Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly

Contact Info

Product

Resources

About